Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02833285
Other study ID # LBPARO
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date May 2015
Est. completion date September 2020

Study information

Verified date July 2019
Source University Hospital, Brest
Contact PERS Jacques-Olivier
Phone 02 98 32 33 84
Email pers@univ-brest.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The inflammatory response involves many players from the immune response, including B lymphocytes. These cells are responsible for the synthesis of immunoglobulins in response to the presence of an antigen. They are characteristic of chronic inflammation. There are several subsets of B cells characterized by specific membrane markers. Once activated, these cells express many factors contributing to tissue destruction seen in periodontitis and particularly in osteoclastogenesis (receptor activator of nuclear factor kappa-B ligand, tumor necrosis factor, interleukin-6, macrophage inflammatory protein-1α and Monocyte Chemoattractant Protein-3).

During the establishment of a periodontal disease, an important inflammatory infiltrate is observed in the gum. This infiltrate is characterized by the presence of many B lymphocytes. B cell subsets in the blood and the gum of patients with periodontitis have been little studied. However, the number of autoreactive B cells (cluster of differentiation (CD)19+, CD5+) has been reported to be higher in the blood of patients with periodontal disease. In the gum, the rate of B and T cells increases with the level of inflammation and is correlated with the severity of the inflammatory process. Activation of B cells is a prerequisite for the progression of gingivitis to periodontitis. B cell distribution could then be an indicator of disease progression, but also allow to study the response to treatment.

The aim of this pilot study is to characterize B cell subsets in the blood and the gum of patients with periodontitis, according to disease activity. Analysis of B cells in the blood could highlight the association of a particular subpopulation with aggressive periodontal disease and evidence a particular biological profile of the host response. The investigators also wish to observe the evolution of this phenotype following an unconventional surgical therapy.

This study would better understand the pathogenesis of periodontal disease and refine the diagnosis, prognosis and treatment of periodontitis, and thus participate in the development of personalized medicine. Biological monitoring of therapeutic effects may be initiated and allow more effectively prevent recurrence.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date September 2020
Est. primary completion date September 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Requiring periodontal surgery

- In good health

- Having signed consent

Exclusion Criteria:

- Minor

- Patient having taken antibiotics in the previous 3 months

- Patients with systemic diseases including chronic inflammatory disease

- Pregnancy

- orthodontic treatment ongoing

Study Design


Locations

Country Name City State
France CHRU de Brest Brest

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Brest

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Phenotype of B cells in the blood and gums 3 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06400069 - Role of NLRP6 in Chronic Periodontitis
Completed NCT05231096 - Comparison of the Effect of Gingival Massage of Aloe-vera Gel and Sidr Honey on Chronic Periodontitis N/A
Completed NCT03203746 - Gingival Crevicular Fluid Levels of Protein Carbonyl Following the Use of Lycopene in Chronic Periodontitis Phase 1/Phase 2
Active, not recruiting NCT03354338 - Amoxicillin to Prevent Bacteria and Inflammatory Biomarkers After Intensive Periodontal Therapy Phase 2
Completed NCT02516111 - Comparison of Autologous PRF, 1% Alendronate and 1.2% Atorvastatin Gel in Chronic Periodontitis Treatment Phase 2/Phase 3
Completed NCT02174146 - Leptin and Visfatin in Diabetic Patients With Periodontitis Before and After Periodontal Therapy N/A
Terminated NCT02568163 - Influence of Stress on Non Surgical Periodontal Treatment N/A
Completed NCT02430519 - Benefits of Platelet Rich Fibrin In Mandibular Molar Furcation Defects N/A
Completed NCT01233765 - Analysis of Neutrophil Response in Chronic Periodontitis N/A
Completed NCT01438333 - Efficacy of INERSAN in Patients With Chronic Periodontitis as Adjunctive to Full Mouth Disinfection N/A
Completed NCT02218515 - Treatment of Intrabony Periodontal Defects With Enamel Matrix Derivatives and Autogenous Bone Graft Phase 4
Completed NCT02197260 - Antimicrobial Therapy as Adjunct to Periodontal Treatment: Effect of Timing Phase 4
Not yet recruiting NCT03270280 - Comparison of Salivary Interleukin-1β and Matrix Metalloproteinase-8 Levels in Individuals With Chronic Periodontitis Phase 2
Not yet recruiting NCT04026828 - Evaluation of Possible Genes in Periodontal Diseases by Genetic Methods
Completed NCT04697199 - The Adjunctive Effect of Probiotics to Non Surgical Treatment of Chronic Periodontitis Phase 1
Completed NCT04643288 - Nanocrystalline Hydroxyapatite Bone Substitute for Treating Periodontal Intrabony Defects N/A
Completed NCT03039244 - Evaluation of Antimicrobial Photodynamic Therapy as an Adjunct to Periodontal Treatment in Smokers N/A
Completed NCT02518152 - Platelet Rich Fibrin+1% Alendronate in Treatment of Chronic Periodontitis Phase 2/Phase 3
Completed NCT03874390 - Effects of Ozone Therapy on Clinical Parameters and Inflammatory Cytokines in Chronic Periodontitis Patients N/A
Completed NCT02898675 - Advantages of Autologous Platelet-Rich Fibrin Membrane on Growth Factor Levels and Periodontal Healing N/A